Skip to main content

Seagen Inc Value Stock - Dividend - Research Selection

Seagen

ISIN: US81181C1045 , WKN: A2QFAQ

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Seagen Requests Director Review Of Unpatentability Decision In Adcetris® Patent PGR

2024-02-29
On February 14, 2024, Seagen requested director review of the PTAB's January 16th Final Written Decision in PGR2021-00030 finding antibody-drug conjugate claims in U.S. Patent No. 10,808,039 ...

PTAB Issues Final Written Decision Finding Seagen Antibody-Drug Conjugate Patent Claims To Be Unpatentable

2024-01-30
On January 16, 2024, the Patent Trial and Appeal Board of the United States Patent and Trademark Office issued a Final Written Decision in a post-grant review of claims in US Patent No. 10,808,039...

Pfizer: Paying Too Much To Boost Revenues

2024-01-06
Pfizer (PFE) has generally paid high prices for M&A, above industry norms. Click here to read more.

Madrigal Pharmaceuticals: A Deeper Look At A Looming NASH Play

2024-01-02
Discover the reasons behind the recent 70% surge in Madrigal Pharmaceuticals, Inc. stock and explore MDGL future potential. Click here for my strategy for MDGL.

The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations

2023-12-28
Pfizer reported strong revenue growth and expanded its presence in the cancer drugs market through a major acquisition. Read why I rate PFE stock a Buy now.